X4 Pharmaceuticals (NASDAQ:XFOR) Raised to Strong-Buy at Zacks Research

X4 Pharmaceuticals (NASDAQ:XFOR) was upgraded by research analysts at Zacks Research to a “strong-buy” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

Several other brokerages also recently weighed in on XFOR. Weiss Ratings restated a “sell (e+)” rating on shares of X4 Pharmaceuticals in a research note on Wednesday, October 8th. HC Wainwright set a $3.50 price objective on shares of X4 Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, August 13th. Finally, Stifel Nicolaus cut their price target on shares of X4 Pharmaceuticals from $30.00 to $9.00 and set a “buy” rating on the stock in a research note on Friday, August 29th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.17.

X4 Pharmaceuticals Trading Down 1.3%

NASDAQ:XFOR opened at $3.10 on Tuesday. X4 Pharmaceuticals has a 52 week low of $1.35 and a 52 week high of $26.83. The firm has a 50 day moving average of $3.34 and a 200 day moving average of $3.27. The company has a quick ratio of 3.05, a current ratio of 3.19 and a debt-to-equity ratio of 19.10. The stock has a market capitalization of $35.37 million, a price-to-earnings ratio of -0.21 and a beta of 0.54.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings results on Friday, August 8th. The company reported ($3.47) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.53) by $1.06. The business had revenue of $1.97 million for the quarter, compared to the consensus estimate of $1.62 million. X4 Pharmaceuticals had a negative return on equity of 375.31% and a negative net margin of 311.15%. As a group, sell-side analysts anticipate that X4 Pharmaceuticals will post -0.68 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Jane Street Group LLC lifted its position in X4 Pharmaceuticals by 112.5% during the second quarter. Jane Street Group LLC now owns 97,344 shares of the company’s stock valued at $185,000 after purchasing an additional 51,544 shares during the period. Rhumbline Advisers grew its holdings in X4 Pharmaceuticals by 5.4% during the first quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock worth $44,000 after acquiring an additional 9,690 shares during the period. Kingdon Capital Management L.L.C. grew its holdings in X4 Pharmaceuticals by 41.8% during the first quarter. Kingdon Capital Management L.L.C. now owns 7,000,000 shares of the company’s stock worth $1,655,000 after acquiring an additional 2,063,000 shares during the period. Pale Fire Capital SE grew its holdings in X4 Pharmaceuticals by 45.2% during the first quarter. Pale Fire Capital SE now owns 2,035,362 shares of the company’s stock worth $481,000 after acquiring an additional 633,398 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its holdings in X4 Pharmaceuticals by 9.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 481,528 shares of the company’s stock worth $114,000 after acquiring an additional 43,320 shares during the period. 72.03% of the stock is currently owned by institutional investors and hedge funds.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.